SCHEMBL6973564

SCHEMBL6973564

COC(=O)C1Cc2cc(NC(=O)OCc3ccccc3)ccc2N1C(=O)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 3/20 0.48
PSEN2 P49810 3/20 0.48
APH1B Q8WW43 3/20 0.48
NCSTN Q92542 3/20 0.48
APH1A Q96BI3 3/20 0.48
PSENEN Q9NZ42 3/20 0.48
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
TP53 P04637 1/20 0.47
MAPT P10636 1/20 0.47
TSHR P16473 1/20 0.47
RAB9A P51151 1/20 0.47
ATM Q13315 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MGLL Q99685 1/20 0.46
MMP8 P22894 2/20 0.45
MMP3 P08254 1/20 0.45
ROCK2 O75116 1/20 0.45
KDM1A O60341 3/20 0.44
MAOA P21397 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6961311 0.87 TSHR (0.49) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6971657 0.84 NPC1 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5764293 0.84 DRD2 (0.53) NPC1RAB9A
SCHEMBL3029392 0.81 TSHR (0.50) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6963286 0.81 ALDH1A1 (0.47) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6961781 0.78 SMN1; SMN2 (0.43) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13711930 0.76 NPC1 (0.54) NPC1RAB9ASMN1; SMN2
SCHEMBL6969247 0.74 ALDH1A1 (0.57) NPC1ALDH1A1TP53MAPTTSHR
SCHEMBL7310845 0.73 NPC1 (0.48) NPC1RAB9A
SCHEMBL6190803 0.72 RAB9A (0.56) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1181288-B1 BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT UPJOHN CO (US) 2003-07-30 EP disclosed
US-20020143009-A1 Novel bicyclic oxazolidinones as antibacterial agents PHARMACIA & UPJOHN 2002-10-03 US disclosed
US-6387896-B1 GRAMNEGATIVE, GRAMPOSITVE BACTERIA PHARMACIA & UPJOHN CO. 2002-05-14 US disclosed
EP-1181288-A1 BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT PHARMACIA & UPJOHN COMPANY (US) 2002-02-27 EP disclosed
WO-2000073301-A1 BICYCLIC OXAZOLIDINONES AS ANTIBACTERIAL AGENT PHARMACIA & UPJOHN COMPANY (US) 2000-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143009-A1 Novel bicyclic oxazolidinones as antibacterial agents OXA1L, MRPL21, RPS4Y1 PSEN1 2422/4885PSEN2 3444/4885APH1B 1724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.